Low circulating insulin-like growth factor I increases atherosclerosis in ApoE-deficient mice.

Some clinical studies have suggested that lower IGF-I levels may be associated with an increased risk of ischemic heart disease. We generated atherosclerosis-prone apolipoprotein E-deficient (ApoE(-/-)) mice with 6T alleles (6T/ApoE(-/-) mice) with a 20% decline in circulating IGF-I and fed these mice and control ApoE(-/-) mice with normal chow or a Western diet for 12 wk to evaluate the effect of low serum IGF-I on atherosclerosis progression. We found that the 6T/ApoE(-/-) phenotype was characterized by an increased atherosclerotic burden, elevated plaque macrophages, and increased proinflammatory cytokine TNF-α levels compared with ApoE(-/-) controls. 6T/ApoE(-/-) mice had similar body weight, blood pressure, serum total cholesterol levels, total plaque and smooth muscle cell apoptosis rates, and circulating levels of endothelial progenitor cells as ApoE(-/-) mice. 6T/ApoE(-/-) mice fed with normal chow had reduced vascular endothelial nitric oxide synthase mRNA levels and a trend to increased aortic expression of chemokine (C-C motif) receptor (CCR)1, CCR2, and monocyte chemoattractant protein-1/chemokine (C-C motif) ligand 2. Western diet-fed 6T/ApoE(-/-) mice had a trend to increased expression of macrophage scavenger receptor-1/scavenger receptor-A, osteopontin, ATP-binding cassette (subfamily A, member 1), and angiotensin-converting enzyme and elevated circulating levels of the neutrophil chemoattractant chemokine (C-X-C motif) ligand 1 (KC). Our data establish a link between lower circulating IGF-I and increased atherosclerosis that has important clinical implications.

[1]  SergiySukhanov,et al.  Smooth Muscle Cell–Specific Insulin-Like Growth Factor-1 Overexpression in Apoe−/− Mice Does Not Alter Atherosclerotic Plaque Burden but Increases Features of Plaque Stability , 2010 .

[2]  P. Delafontaine,et al.  IGF-1, oxidative stress and atheroprotection , 2010, Trends in Endocrinology & Metabolism.

[3]  D. Greaves,et al.  Inflammatory cell recruitment in cardiovascular disease: murine models and potential clinical applications. , 2010, Clinical science.

[4]  P. Delafontaine,et al.  Growth hormone-releasing peptide-2 suppresses vascular oxidative stress in ApoE-/- mice but does not reduce atherosclerosis. , 2009, Endocrinology.

[5]  K. Ley,et al.  Opening the flood-gates: how neutrophil-endothelial interactions regulate permeability. , 2009, Trends in immunology.

[6]  N. Leitinger,et al.  Induction of CCR2-dependent macrophage accumulation by oxidized phospholipids in the air-pouch model of inflammation. , 2009, Arthritis and rheumatism.

[7]  G. Brabant,et al.  Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. , 2009, The Journal of clinical endocrinology and metabolism.

[8]  P. Hildebrandt,et al.  IGF1 as predictor of all cause mortality and cardiovascular disease in an elderly population. , 2009, European journal of endocrinology.

[9]  D. Seals,et al.  Aging is associated with greater nuclear NFκB, reduced IκBα, and increased expression of proinflammatory cytokines in vascular endothelial cells of healthy humans , 2008, Aging cell.

[10]  J. Björkegren,et al.  Correlation of serum IGF‐I and IGFBP‐1 and ‐3 to cardiovascular risk indicators and early carotid atherosclerosis in healthy middle‐aged men , 2008, Clinical endocrinology.

[11]  SergiySukhanov,et al.  IGF-1 Reduces Inflammatory Responses, Suppresses Oxidative Stress, and Decreases Atherosclerosis Progression in ApoE-Deficient Mice , 2007 .

[12]  N. Rosenthal,et al.  Local expression of IGF‐1 accelerates muscle regeneration by rapidly modulating inflammatory cytokines and chemokines , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  T. Peng,et al.  A redox-sensitive pathway mediates oxidized LDL-induced downregulation of insulin-like growth factor-1 receptors⃞s⃞ The online version of this article (available at http://www.jlr.org) contains an additional figure. Published, JLR Papers in Press, April 1, 2005. DOI 10.1194/jlr.M400478-JLR200 , 2005, Journal of Lipid Research.

[14]  P. Delafontaine,et al.  Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[15]  Ying Wang,et al.  Stimulatory effect of IGF-I and VEGF on eNOS message, protein expression, eNOS phosphorylation and nitric oxide production in rat glomeruli, and the involvement of PI3-K signaling pathway. , 2004, Nitric oxide : biology and chemistry.

[16]  P. Delafontaine,et al.  Insulin-Like Growth Factor-1 Receptor Activation Inhibits Oxidized LDL-Induced Cytochrome C Release and Apoptosis via the Phosphatidylinositol 3 Kinase/Akt Signaling Pathway , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[17]  H. Kotani,et al.  Adiposity Elevates Plasma MCP-1 Levels Leading to the Increased CD11b-positive Monocytes in Mice* , 2003, Journal of Biological Chemistry.

[18]  I. Jonsdottir,et al.  GH and IGF-I regulate the expression of endothelial nitric oxide synthase (eNOS) in cardiovascular tissues of hypophysectomized female rats. , 2002, European journal of endocrinology.

[19]  T. Jørgensen,et al.  Heart Disease : A Population-Based Case-Control Study Low Serum Insulin-Like Growth Factor I Is Associated With Increased Risk of Ischemic , 2002 .

[20]  G. Churchill,et al.  Generation of a New Congenic Mouse Strain to Test the Relationships Among Serum Insulin‐like Growth Factor I, Bone Mineral Density, and Skeletal Morphology In Vivo , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  M. Brink,et al.  Decreased expression of insulin-like growth factor-1 and apoptosis of vascular smooth muscle cells in human atherosclerotic plaque. , 2001, Journal of molecular and cellular cardiology.

[22]  J. Knowles,et al.  Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-)Apoe(-/-) mice are ameliorated by enalapril treatment. , 2000, The Journal of clinical investigation.

[23]  S. Bennett,et al.  Pleiotropic effects of growth hormone and insulin-like growth factor (IGF)-1 on biological aging: inferences from moderate caloric-restricted animals. , 1999, The journals of gerontology. Series A, Biological sciences and medical sciences.

[24]  Lee M. Silver,et al.  Mouse Genetics: Concepts and Applications , 1995 .

[25]  M. Hammerman,et al.  Insulin-like growth factors and aging. , 1987, Endocrinology and metabolism clinics of North America.

[26]  E. Baráth,et al.  Fundamentals of Biostatistics. , 1992 .